SCHEMBL20503569

SCHEMBL20503569

CS(=O)(=O)Nc1cc[nH]n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
KEAP1 Q14145 2/20 0.39
PGR P06401 2/20 0.36
GLO1 Q04760 2/20 0.36
AR P10275 2/20 0.36
ALOX15 P16050 1/20 0.36
NR3C1 P04150 1/20 0.36
NR3C2 P08235 1/20 0.36
SCN9A Q15858 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
JAK2 O60674 2/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28335271 0.76
SCHEMBL1858705 0.75
SCHEMBL1093985 0.73 ALDH1A1 (0.50) HPGDKDM4EALDH1A1LMNAKEAP1
SCHEMBL6594119 0.72 HPGD (0.52) HPGDKDM4EALDH1A1LMNAAR
SCHEMBL7013955 0.72 NR3C1 (0.45) HTTHPGDSMN1; SMN2KDM4EALDH1A1
SCHEMBL6365958 0.72 KDM4E (0.54) HPGDKDM4EALDH1A1PGRGLO1
SCHEMBL6582449 0.71 SMN1; SMN2 (0.54) HTTSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL1123002 0.71 MMP13 (0.33) HTTHPGDSMN1; SMN2KDM4EALDH1A1
SCHEMBL47767 0.70
SCHEMBL5565365 0.70 CA12 (0.54) HPGDSMN1; SMN2ALDH1A1LMNACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258340-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2025-03-25 US disclosed
CN-116473965-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2025-03-18 CN disclosed
EP-3634404-B1 PYRAZOLE MAGL INHIBITORS H LUNDBECK AS (DK) 2024-11-20 EP disclosed
CN-116473965-A Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-07-25 CN disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 EP disclosed
CN-110678177-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-06-13 CN disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 US disclosed
CN-110678456-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-05-02 CN disclosed
EP-3630744-B1 PYRAZOLE MAGL INHIBITORS H LUNDBECK AS (DK) 2023-01-25 EP disclosed
US-20200087304-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2020-03-19 US disclosed
CN-110678177-A Pyrazole MAGL inhibitors 隆德贝克拉荷亚研究中心有限公司 2020-01-10 CN disclosed
CN-110678456-A Pyrazole MAGL inhibitors 隆德贝克拉荷亚研究中心有限公司 2020-01-10 CN disclosed
US-20190256494-A1 PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2019-08-22 US disclosed
US-20190256494-A1 PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2019-08-22 US disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 US disclosed
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-11-29 US disclosed
WO-2018217805-A1 PYRAZOLE MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-11-29 WO disclosed
WO-2018217809-A1 PYRAZOLE MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-11-29 WO disclosed
EP-3377060-A1 PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME Abide Therapeutics, Inc. (US) 2018-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL HTT 4418/4885HPGD 770/4885SMN1; SMN2 3430/4885
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL HTT 4418/4885HPGD 770/4885SMN1; SMN2 3430/4885
US-12258340-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL HTT 4464/4885HPGD 1010/4885SMN1; SMN2 3564/4885
US-10266497-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL HTT 4418/4885HPGD 770/4885SMN1; SMN2 3430/4885
US-20200087304-A1 PYRAZOLE MAGL INHIBITORS MAGI3, MAG, PYM1 HTT 4177/4885HPGD 1460/4885SMN1; SMN2 2525/4885
US-11655217-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL HTT 4464/4885HPGD 1010/4885SMN1; SMN2 3564/4885
US-20190256494-A1 PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME ABHD6, ABHD16A, RABL6 HTT 3161/4885HPGD 263/4885SMN1; SMN2 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.